東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back to Search results for [ null ]

Switch To: Labeled | MARC Mode | ISBD

The effect of the bisphosphonate, Al...

State University of New York at Buffalo., Oral Sciences.

Linked to FindBook

Google Book

Amazon

博客來

The effect of the bisphosphonate, Alendronate, on primary human alveolar bone cells.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	The effect of the bisphosphonate, Alendronate, on primary human alveolar bone cells./
Author:	Almojaly, Saud.
Description:	61 p.
Notes:	Advisers: Rosemary Dziak; Sebastian Ciancio.
Contained By:	Masters Abstracts International46-06.
Subject:	Biology, Cell. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=1453398
ISBN:	9780549559740

The effect of the bisphosphonate, Alendronate, on primary human alveolar bone cells.
Almojaly, Saud.

The effect of the bisphosphonate, Alendronate, on primary human alveolar bone cells. - 61 p.

Advisers: Rosemary Dziak; Sebastian Ciancio.

Thesis (M.S.)--State University of New York at Buffalo, 2008.

Background. Bisphosphonates are synthetic analogues of inorganic pyrophosphate. Bisphosphonates are the most commonly antiresorptive agents used in the treatment of diseases involving excessive osteoclast activity, such Paget's disease, tumor associated bone disease and osteoporosis. Bisphosphonates have been shown to inhibit osteoclast-mediated bone resorption and to have anabolic effects on osteoblasts by promoting osteoblast proliferation and maturation. Bisphosphonate-associated osteonecrosis in oral cavity is a major complication associated with bisphosphonates in particularly in the intravenous class. We hypothesized that bisphosphonates have a proliferative and osteogenic effects on osteoblasts obtained from alveolar bone, distinct from the effects on osteoblasts obtained from other parts of the body. The aim of this study was to determine if the bisphosphonate, Alendronate, may enhance or inhibit the proliferation and osteogenesis of primary human osteoblasts derived from alveolar bone cells and to compared the effect of Alendronate alone to PDGF, PTH and to a mixture of Alendronate and either one of these hormones.

ISBN: 9780549559740Subjects--Topical Terms:

1017686
Biology, Cell.

The effect of the bisphosphonate, Alendronate, on primary human alveolar bone cells.
LDR:03564nam 2200337 a 45 001 858320
005 20100712
008 100712s2008 ||||||||||||||||| ||eng d
020 $a 9780549559740
035 $a (UMI)AAI1453398
035 $a AAI1453398
040 $a UMI $c UMI
100 1 $a Almojaly, Saud. $3 1025371
245 1 4 $a The effect of the bisphosphonate, Alendronate, on primary human alveolar bone cells.
300 $a 61 p.
500 $a Advisers: Rosemary Dziak; Sebastian Ciancio.
500 $a Source: Masters Abstracts International, Volume: 46-06, page: 3210.
502 $a Thesis (M.S.)--State University of New York at Buffalo, 2008.
520 $a Background. Bisphosphonates are synthetic analogues of inorganic pyrophosphate. Bisphosphonates are the most commonly antiresorptive agents used in the treatment of diseases involving excessive osteoclast activity, such Paget's disease, tumor associated bone disease and osteoporosis. Bisphosphonates have been shown to inhibit osteoclast-mediated bone resorption and to have anabolic effects on osteoblasts by promoting osteoblast proliferation and maturation. Bisphosphonate-associated osteonecrosis in oral cavity is a major complication associated with bisphosphonates in particularly in the intravenous class. We hypothesized that bisphosphonates have a proliferative and osteogenic effects on osteoblasts obtained from alveolar bone, distinct from the effects on osteoblasts obtained from other parts of the body. The aim of this study was to determine if the bisphosphonate, Alendronate, may enhance or inhibit the proliferation and osteogenesis of primary human osteoblasts derived from alveolar bone cells and to compared the effect of Alendronate alone to PDGF, PTH and to a mixture of Alendronate and either one of these hormones.
520 $a Methods. Human alveolar bone cells were obtained during routine oral surgical procedure from healthy adult subjects. Following treatment with Alendronate (at 10-8M), PDGF, PTH and a combination of Alendronate and either PDGF and PTH at different time periods (24, 48 and72 hours), cells were examined for maturation with the alkaline phosphates assay and RT-PCR for gene expression. The effect of Alendronate on proliferation was assessed with the 3H-thymidine assay. The results were analyzed by (ANOVA) followed by Tukey HSD post hoc comparison analysis.
520 $a Results. Alendronate increased alkaline phosphatase activity at 24 and 48 hours. The Proliferation rate was enhanced by Alendronate at 48 hours. Alendronate decreased the gene expression of type I collagen at 24 and 48 hours but promoted the expression at 72 hours. Mixing Alendronate and PDGF decreased the alkaline phosphatase activity at 24 and 48 hours and also decreased the proliferation rate at 48 hours but enhanced the gene expression of type I collagen at all time points, whereas combining Alendronate and PTH decreased the proliferation rate and the gene expression.
520 $a Conclusion. Alendronate demonstrates positive anabolic effects on primary human osteoblasts derived from alveolar bone. There is no evidence of synergy between Alendronate and PTH, but the possibility exists that PDGF may decrease the osteogenic effect of the bisphosphonate.
590 $a School code: 0656.
650 4 $a Biology, Cell. $3 1017686
650 4 $a Biology, General. $3 1018625
650 4 $a Health Sciences, Dentistry. $3 1019378
690 $a 0306
690 $a 0379
690 $a 0567
710 2 $a State University of New York at Buffalo. $b Oral Sciences. $3 1025370
773 0 $t Masters Abstracts International $g 46-06.
790 $a 0656
790 1 0 $a Ciancio, Sebastian, $e advisor
790 1 0 $a Dziak, Rosemary, $e advisor
791 $a M.S.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=1453398